GSK joins the grant reporting game

Share this article:
GlaxoSmithKline will join Pfizer and Eli Lilly in reporting its educational and charitable grants.

The company will provide quarterly reports on grants to hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups and CME companies starting in February. 

“GSK sponsors a range of third-party independent educational programs to increase awareness and knowledge of health-related issues,” said GSK's then-president, North American Pharmaceuticals Chris Viehbacher in a statement. “By publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of healthcare for patients.”

Lilly began reporting its grants publicly in May of 2007, and Pfizer followed suit a year later. In March, AstraZeneca vowed to publish grant information biannually.

In April, responding to an inquiry by Sen. Charles Grassley (R-IA) demanding to know whether they would follow Lilly's lead, several companies, including Bristol-Myers Squibb, Medtronic and Boston Scientific, also agreed to begin making information on educational grants and payments to physicians public, while others, including Abbott, Amgen and Merck, told the senator they were working on it. 

Only one of the firms Grassley wrote—Schering-Plough—declined outright. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?